Valneva SE

EN Texto en inglés Aún no hay artículo en tu idioma: extracto en inglés.

Valneva SE is a specialty vaccine company registered in Saint-Herblain, France, developing, producing and commercializing vaccines for infectious diseases. It has manufacturing sites in Livingston, Scotland; Solna, Sweden, and Vienna, Austria; with other offices in France, Canada and the United States. Valneva was founded in 2013 through the merger of Austrian company Intercell and French company Vivalis SA. It has been listed since May 2013 on Euronext Paris Paris and since May 2021 on the US Nasdaq. Valneva used to be listed on the Vienna Stock Exchange. Vaccines marketed by Valneva include Ixiaro, a vaccine against Japanese encephalitis (approved in Europe, America and Australia) Dukoral, a vaccine against cholera and LT-ETEC (approved in Europe, Canada and Australia) and IXCHIQ, a vaccine against the chikungunya virus (live-attenuated, single-dose). Some of its candidates have failed in clinical trials: VLA43, a therapeutic vaccine against Pseudomonas aeruginosa, V710, a therapeutic vaccine against Staphylococcus aureus (in collaboration with Merck), and IC41, therapeutic vaccine against hepatitis C. Valenava announced positive results of its Phase 1 clinical trial in November 2025, but added that despite the medical need, regulatory pathways and market opportunities for potential Zika vaccines remain uncertain unless the company finds a major investor. Valneva along with Dynavax Technologies developed a candidate inactivated whole virus vaccine against COVID-19, VLA2001, derived from its Ixiaro Japanese encephalitis vaccine, which underwent a Phase 1/2 trial in the United Kingdom. The Phase 1/2 trial had 150 participants, testing three dose levels for safety, tolerability, and immunogenicity. The trial was expected to be complete by 15 February 2021, with full reporting completed by August 2021.